Article Sidebar

PDF
Date Published: 12/04/2023
Abstract Views: 90
Views PDF: 82
DOI: https://doi.org/10.51298/vmj.v525i1A.4936
Issue
Vol. 525 No. 1A (2023)
Section
Các bài báo
How to Cite
Đỗ , H. K. ., & Nguyễn, T. N. H. . (2023). ASSESSING THE TREATMENT RESULTS OF DOUBLET PLATINUM-BASED CHEMOTHERAPY IN METASTATIC/RECURRENT SQUAMOUS CELL HEAD AND NECK CANCER. Vietnam Medical Journal, 525(1A). https://doi.org/10.51298/vmj.v525i1A.4936

ASSESSING THE TREATMENT RESULTS OF DOUBLET PLATINUM-BASED CHEMOTHERAPY IN METASTATIC/RECURRENT SQUAMOUS CELL HEAD AND NECK CANCER

Hùng Kiên Đỗ 1,, Thị Như Hoa Nguyễn1
1 k hospital

Main Article Content

Abstract

Objective: Assessing treatment responses of doublet platinum-based chemotherapy in patients with recurrent/metastatic squamous cell head and neck cancer at K Hospital. Patients and method: Retrospective and prospective analysis of 62 recurrent/metastatic squamous cell head and neck cancer patients treated with first-line doublet platinum-based chemotherapy at K Hospital from 12/2018 to 12/2022. Results: Majority of patients were male (77.4%) with age < 65 years old (69.4%). ECOG performance status 1 was observed in 59.7%. Metastatic stage at diagnosis was 75.8%. Lung metastasis was observed in 59.7%. Majority of patients received cisplatin-based regimens (60.9%). Partial response rate was seen in 27.4% and disease control rate was 59.7%. Cisplatin regimen was associated with higher overall response rate compared to carboplatin regimen. Conclusion: Doublet platinum-based chemotherapy for the treatment of recurrent/metastatic squamous cell head and neck cancer had improved clinical symptoms with a response rate of 27.4%.

Article Details

Keywords

squamous cell head and neck cancer, recurrent/metastatic stage, doublet platinum-based chemotherapy

References

1. Bertino JR, Mosher MB, Deconti RC. Chemotherapy of cancer of the head and neck. Cancer. 1973;31(5):1141-1149. doi:10.1002/ 1097-0142(197305)31:5<1141::AID-CNCR2820310515>3.0.CO;2-R
2. Wittes RE, Cvitkovic E, Shah J, Gerold FP, Strong EW. CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep. 1977; 61(3):359-366.
3. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10 (8):1245-1251. doi:10.1200/JCO.1992.10.8.1245
4. Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992; 10(2):257-263. doi:10.1200/ JCO.1992.10.2.257
5. Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med. 2008;359(11):1116-1127. doi:10.1056/NEJMoa0802656
6. Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021; 22(4):463-475. doi:10.1016/S1470-2045 (20)30755-5
7. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7